Last reviewed · How we verify

docetaxel plus oxaliplatin and capecitabine

LiNing · Phase 3 active Small molecule

docetaxel plus oxaliplatin and capecitabine is a chemotherapeutic agents Small molecule drug developed by LiNing. It is currently in Phase 3 development for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer. Also known as: Three medicine combined.

Docetaxel works by inhibiting microtubule dynamics, while oxaliplatin induces DNA damage and interstrand crosslinks, and capecitabine is a thymidylate synthase inhibitor.

Docetaxel works by inhibiting microtubule dynamics, while oxaliplatin induces DNA damage and interstrand crosslinks, and capecitabine is a thymidylate synthase inhibitor. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.

At a glance

Generic namedocetaxel plus oxaliplatin and capecitabine
Also known asThree medicine combined
SponsorLiNing
Drug classchemotherapeutic agents
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Docetaxel, oxaliplatin, and capecitabine are chemotherapeutic agents that target rapidly dividing cancer cells. Docetaxel binds to tubulin and prevents microtubule formation, leading to cell cycle arrest and apoptosis. Oxaliplatin forms platinum-DNA adducts, which interfere with DNA replication and transcription, causing cell death. Capecitabine is converted to 5-fluorouracil, which inhibits thymidylate synthase, leading to DNA damage and cell death.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about docetaxel plus oxaliplatin and capecitabine

What is docetaxel plus oxaliplatin and capecitabine?

docetaxel plus oxaliplatin and capecitabine is a chemotherapeutic agents drug developed by LiNing, indicated for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.

How does docetaxel plus oxaliplatin and capecitabine work?

Docetaxel works by inhibiting microtubule dynamics, while oxaliplatin induces DNA damage and interstrand crosslinks, and capecitabine is a thymidylate synthase inhibitor.

What is docetaxel plus oxaliplatin and capecitabine used for?

docetaxel plus oxaliplatin and capecitabine is indicated for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer.

Who makes docetaxel plus oxaliplatin and capecitabine?

docetaxel plus oxaliplatin and capecitabine is developed by LiNing (see full LiNing pipeline at /company/lining).

Is docetaxel plus oxaliplatin and capecitabine also known as anything else?

docetaxel plus oxaliplatin and capecitabine is also known as Three medicine combined.

What drug class is docetaxel plus oxaliplatin and capecitabine in?

docetaxel plus oxaliplatin and capecitabine belongs to the chemotherapeutic agents class. See all chemotherapeutic agents drugs at /class/chemotherapeutic-agents.

What development phase is docetaxel plus oxaliplatin and capecitabine in?

docetaxel plus oxaliplatin and capecitabine is in Phase 3.

What are the side effects of docetaxel plus oxaliplatin and capecitabine?

Common side effects of docetaxel plus oxaliplatin and capecitabine include Neutropenia, Diarrhea, Fatigue, Nausea, Vomiting.

Related